Jama Oncology最新文献

{"title":"Hormone Deprivation-Free Survival-Inequities Persist in Research Priorities for Patients With Cancer.","authors":"Benjamin Hopkins, Reshma Jagsi, Mylin Torres","doi":"10.1001/jamaoncol.2024.2142","DOIUrl":"10.1001/jamaoncol.2024.2142","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1309-1310"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141761832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When Best Care Takes a Back Seat to the Bottom Line.","authors":"Jonathan E Leeman, Zhaohui Han, Daphne A Haas-Kogan","doi":"10.1001/jamaoncol.2024.2485","DOIUrl":"10.1001/jamaoncol.2024.2485","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1311-1312"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relapse Patterns in Early-Stage Endometrial Cancer Based on Molecular Classification-Reply.","authors":"Otilia Ciobanu, Yixuan He, David C Qian","doi":"10.1001/jamaoncol.2024.3242","DOIUrl":"10.1001/jamaoncol.2024.3242","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1440"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Lazertinib in Patients With EGFR-Variant Non-Small Cell Lung Cancer.","authors":"Haiying Cheng","doi":"10.1001/jamaoncol.2024.2607","DOIUrl":"10.1001/jamaoncol.2024.2607","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1352-1353"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAMA Oncology.","authors":"","doi":"10.1001/jamaoncol.2023.4664","DOIUrl":"https://doi.org/10.1001/jamaoncol.2023.4664","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":"10 10","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.","authors":"Catherine H Marshall, Benjamin A Teply, Jiayun Lu, Lia Oliveira, Hao Wang, Shifeng S Mao, W Kevin Kelly, Channing J Paller, Mark C Markowski, Samuel R Denmeade, Serina King, Rana Sullivan, Elai Davicioni, James A Proudfoot, Mario A Eisenberger, Michael A Carducci, Tamara L Lotan, Emmanuel S Antonarakis","doi":"10.1001/jamaoncol.2024.3074","DOIUrl":"10.1001/jamaoncol.2024.3074","url":null,"abstract":"<p><strong>Importance: </strong>Olaparib is a poly(adenosine diphosphate-ribose) polymerase inhibitor that provides benefit in combination with hormonal therapies in patients with metastatic prostate cancer who harbor homologous recombination repair (HRR) alterations. Its efficacy in the absence of androgen deprivation therapy has not been tested.</p><p><strong>Objective: </strong>To determine the activity of olaparib monotherapy among patients with high-risk biochemically recurrent (BCR) prostate cancer after radical prostatectomy.</p><p><strong>Design, setting, and participants: </strong>This phase 2, single-arm nonrandomized controlled trial enrolled genetically unselected patients across 4 sites in the US from May 2017 to November 2022. Eligible patients had BCR disease following radical prostatectomy, a prostate-specific antigen (PSA) doubling time of 6 months or shorter, an absolute PSA value of 1.0 ng/mL or higher, and a testosterone level of 150 ng/dL or higher.</p><p><strong>Intervention: </strong>Treatment was with olaparib, 300 mg, by mouth twice daily until doubling of the baseline PSA, clinical or radiographic progression, or unacceptable toxic effects.</p><p><strong>Main outcome and measure: </strong>The primary end point was a confirmed 50% or higher decline in PSA from baseline (PSA50). Key secondary end points were outcomes by HRR alteration status, as well as safety and tolerability.</p><p><strong>Results: </strong>Of the 51 male patients enrolled (mean [SD] age, 63.8 [6.8] years), 13 participants (26%) had a PSA50 response, all within the HRR-positive group (13 of 27 participants [48%]). All 11 participants with BRCA2 alterations experienced a PSA50 response. Common adverse events were fatigue in 32 participants (63%), nausea in 28 (55%), and leukopenia in 22 (43%), and were consistent with known adverse effects of olaparib.</p><p><strong>Conclusions and relevance: </strong>In this nonrandomized controlled trial, olaparib monotherapy led to high and durable PSA50 response rates in patients with BRCA2 alterations. Olaparib warrants further study as a treatment strategy for some patients with BCR prostate cancer but does not have sufficient activity in those without HRR alterations and should not be considered for those patients.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT03047135.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1400-1408"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11342218/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transperineal vs Transrectal Prostate Biopsy-The PREVENT Randomized Clinical Trial.","authors":"Jim C Hu, Melissa Assel, Mohammad E Allaf, Andrew J Vickers, Behfar Ehdaie, Andrew J Cohen, David A Green, Ahmed Ghazi, Benjamin T Ristau, Keith J Kowalczyk, Arvin K George, Hiten D Patel, Jeffrey S Montgomery, Misop Han, Michael Rezaee, Christian P Pavlovich, Neal A Patel, Ashley E Ross, Shilajit D Kundu, Gerald J Wang, Jonathan E Shoag, Nirmish Singla, Kristian Stensland, Michael A Gorin, Anthony J Schaeffer, Edward M Schaeffer","doi":"10.1001/jamaoncol.2024.4000","DOIUrl":"10.1001/jamaoncol.2024.4000","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11413751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic Body Radiotherapy for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer.","authors":"Chen Hu","doi":"10.1001/jamaoncol.2024.2905","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.2905","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer.","authors":"Christopher W Wheldon","doi":"10.1001/jamaoncol.2024.1586","DOIUrl":"10.1001/jamaoncol.2024.1586","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1167-1168"},"PeriodicalIF":28.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141312017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial.","authors":"Nasser Altorki, Xiaofei Wang, Bryce Damman, David R Jones, Dennis Wigle, Jeffrey Port, Massimo Conti, Ahmad S Ashrafi, Moishe Liberman, Rodney Landreneau, Kazuhiro Yasufuku, Stephen Yang, John D Mitchell, Robert Keenan, Thomas Bauer, Daniel Miller, David Kozono, Jennifer Mentlick, Everett Vokes, Thomas E Stinchcombe","doi":"10.1001/jamaoncol.2024.2491","DOIUrl":"10.1001/jamaoncol.2024.2491","url":null,"abstract":"<p><strong>Importance: </strong>The randomized clinical trial Cancer and Leukemia Group B (CALGB) 140503 showed that for patients with clinically staged T1N0 non-small cell lung cancer (NSCLC; ≤2 cm), sublobar resections were associated with similar oncological outcomes to those after lobar resection. The association of the extent of parenchymal resection with recurrence and survival in patients with tumors pathologically upstaged to T2 based on visceral pleural invasion (VPI) is controversial.</p><p><strong>Objective: </strong>To determine survival and recurrence rates in patients with small peripheral pT2 NSCLC (≤2 cm) that was treated by either lobar or sublobar resection in CALGB 140503.</p><p><strong>Design, participants, and setting: </strong>CALGB 140503, a randomized multicenter noninferiority trial, included 697 patients with small peripheral NSCLC that was clinically staged as T1N0. Enrollment was from June 2007 through March 2017 at 83 participating institutions, and after a median follow-up of 7 years, the primary outcome of disease-free survival after sublobar resection was noninferior to that after lobar resection.</p><p><strong>Intervention: </strong>Lobar or sublobar resection.</p><p><strong>Main outcomes and measures: </strong>Survival end points were estimated by the Kaplan-Meier estimator. Hazard ratios and 95% CIs were estimated using stratified Cox proportional hazard models.</p><p><strong>Results: </strong>Of 679 participants, 390 (57.4%) were female, and the median (range) age was 67.8 (37.8-89.7) years. Among 697 patients randomized, 566 (81.2%) had pT1 tumors (no VPI) and 113 (16.2%) had pT2 tumors (VPI). Five-year disease-free survival was 65.9% (95% CI, 61.9%-70.2%) in patients with pT1 compared with 53.3% (95% CI, 44.3%-64.1%) in patients with pT2 tumors (stratified log-rank: P = .02). Disease recurrence developed in 27.6% of patients with pT1 (locoregional only: 60 [10.8%]; distant only: 81 [14.6%]) and 41.6% of those with pT2 (locoregional only: 17 [15.0%]; distant only: 27 [23.9%]). Five-year recurrence-free survival was 73.1% (95% CI, 69.2%-77.1%) for pT1 tumors and 58.2% (95% CI, 49.2%-68.8%) for pT2 tumors (stratified log-rank: P = .01). There were no intergroup differences in disease-free or recurrence-free survival based on the extent of parenchymal resection.</p><p><strong>Conclusions and relevance: </strong>The results of this secondary analysis suggest that compared with patients with tumors without VPI, patients who had tumors with VPI had worse disease-free and recurrence-free survival and a higher rate of local and distant disease recurrence. These high rates of recurrence were independent of the extent of parenchymal resection, and these data support the inclusion of these patients in adjuvant therapy trials.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT0049933.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1179-1186"},"PeriodicalIF":28.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11295064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}